Cografting of carotid body cells improves the long-term survival, fiber outgrowth and functional effects of grafted dopaminergic neurons

Regenerative Medicine

Volumn 7, Issue 3, 2012, Pages 309-322

  Rodriguez Pallares, Jannette ^a   Joglar, Belen ^a   Muñoz Manchado, Ana B ^b   Villadiego, Javier ^b   Toledo Aral, Juan J ^b   Labandeira Garcia, Jose L ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

carotid body; cell therapy; dopamine; GDNF; neuroprotection; Parkinson; rat; transplantation

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR;

AMPHETAMINE INDUCED ROTATION TEST; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CAROTID BODY; CAROTID BODY CELL; CELL AGGREGATION; CELL COGRAFTING; CELL SURVIVAL; CELL SUSPENSION; CELL TRANSPLANTATION; CONTROLLED STUDY; CORPUS STRIATUM; CYLINDER TEST; DENERVATION; DOPAMINERGIC NERVE CELL; EXPERIMENTAL TEST; FEMALE; FUNCTIONAL ASSESSMENT; MESENCEPHALON; MOTOR PERFORMANCE; NERVE FIBER GROWTH; NEUROBLAST; NONHUMAN; PRIORITY JOURNAL; PROCEDURES CONCERNING CELLS; PROTEIN CONTENT; RAT; REINNERVATION; SUBSTANTIA NIGRA PARS COMPACTA;

AMPHETAMINE; ANIMALS; CAROTID BODY; CELL AGGREGATION; CELL SURVIVAL; DOPAMINERGIC NEURONS; FEMALE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; MESENCEPHALON; MOTOR ACTIVITY; NEOSTRIATUM; NERVE FIBERS; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; ROTATION; SUBSTANTIA NIGRA; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 84861316762     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme.12.22     Document Type: Article

References (77)

1. Kordower JH, Freeman TB, Snow BJ et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N. Engl. J. Med. 332, 1118-1124 (1995).
2. Lindvall O, Sawle G, Widner H et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann. Neurol. 35, 172-180 (1994).
3. Freed CR, Greene PE, Breeze RE et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 344, 710-719 (2001).
4. Olanow CW, Goetz CG, Kordower JH et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann. Neurol. 54, 403-414 (2003).
5. Brundin P, Barker RA, Parmar M. Neural grafting in Parkinson's disease problems and possibilities. Prog. Brain Res. 184, 265-294 (2010).
6. Nikkhah G, Rosenthal C, Falkenstein G, Roedter A, Papazoglou A, Brandis A. Microtransplantation of dopaminergic cell suspensions: further characterization and optimization of grafting parameters. Cell Transplant. 18, 119-133 (2009).
7. Parish CL, Castelo-Branco G, Rawal N et al. Wnt5a-treated midbrain neural stem cells improve dopamine cell replacement therapy in Parkinsonian mice. J. Clin. Invest. 118, 149-160 (2008).
8. Snyder BJ, Olanow CW. Stem cell treatment for Parkinson's disease: an update for 2005. Curr. Opin. Neurol. 18, 376-385 (2005).
9. Villaescusa JC, Arenas E. Transplantable midbrain dopamine neurons: a moving target. Exp. Neurol. 222, 173-178 (2010).
10. Beck KD, Valverde J, Alexi T et al. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature 373, 339-344 (1995).
11. Lin LF, Doherty DH, Lile, JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260, 1130-1132 (1993).
12. Pascual A, Hidalgo-Figueroa M, Gomez-Diaz R, Lopez-Barneo J. GDNF and protection of adult central catecholaminergic neurons. J. Mol. Endocrinol. 46, R83-R92 (2011).
13. Tomac A, Lindqvist E, Lin LF et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373, 335-339 (1995).
14. Lang AE, Gill S, Patel NK et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 59, 459-466 (2006).
15. Love S, Plaha P, Patel NK, Hotton GR, Brooks DJ, Gill SS. Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat. Med. 11, 703-704 (2005).
16. Yasuhara T, Shingo T, Date I. Glial cell line-derived neurotrophic factor (GDNF) therapy for Parkinson's disease. Acta Med. Okayama 61, 51-56 (2007).
17. Apostolides C, Sanford E, Hong M, Mendez I. Glial cell line-derived neurotrophic factor improves intrastriatal graft survival of stored dopaminergic cells. Neuroscience 83, 363-372 (1998).
18. Mehta V, Hong M, Spears J, Mendez I. Enhancement of graft survival and sensorimotor behavioral recovery in rats undergoing transplantation with dopaminergic cells exposed to glial cell line-derived neurotrophic factor. J. Neurosurg. 88, 1088-1095 (1998).
19. Rosenblad C, Martinez-Serrano A, Björklund A. Glial cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts. Neuroscience 75, 979-985 (1996).
20. Torres EM, Monville C, Lowenstein PR, Castro MG, Dunnett SB. Delivery of sonic hedgehog or glial derived neurotrophic factor to dopamine-rich grafts in a rat model of Parkinson's disease using adenoviral vectors increased yield of dopamine cells is dependent on embryonic donor age. Brain Res. Bull. 68, 31-41 (2005).
21. Yurek DM. Glial cell line-derived neurotrophic factor improves survival of dopaminergic neurons in transplants of fetal ventral mesencephalic tissue. Exp. Neurol. 153, 195-202 (1998).
22. Yurek DM, Flectcher AM, Kowalczyk TH, Padegimas L, Cooper MJ. Compacted DNA nanoparticle gene transfer of GDNF to the rat striatum enhances the survival of grafted fetal dopamine neurons. Cell Transplant. 18, 1183-1196 (2009).
23. Ostenfeld T, Tai YT, Martin P, Déglon N, Aebischer P, Svendsen CN. Neurospheres modified to produce glial cell line-derived neurotrophic factor increase the survival of transplanted dopamine neurons. J. Neurosci. Res. 69, 955-965 (2002).
24. Sautter J, Tseng JL, Braguglia D et al. Implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor improve survival, growth, and function of fetal dopaminergic grafts. Exp. Neurol. 149, 230-236 (1998).
25. Georgievska B, Carlsson T, Lacar B, Winkler C, Kirik D. Dissociation between short-term increased graft survival and long-term functional improvements in Parkinsonian rats overexpressing glial cell line-derived neurotrophic factor. Eur. J. Neurosci. 20, 3121-3130 (2004).
26. Winkler C, Georgievska B, Carlsson T, Lacar B, Kirik D. Continuous exposure to glial cell line-derived neurotrophic factor to mature dopaminergic transplants impairs the graft's ability to improve spontaneous motor behavior in parkinsonian rats. Neuroscience 141, 521-531 (2006).
27. Espejo EF, Montoro RJ, Armengol JA, Lápez-Barneo J. Cellular and functional recovery of Parkinsonian rats after intrastriatal transplantation of carotid body cell aggregates. Neuron 20, 197-206 (1998).
28. Luquin MR, Montoro RJ, Guillén J et al. Recovery of chronic parkinsonian monkeys by autotransplants of carotid body cell aggregates into putamen. Neuron 22, 743-750 (1999).
29. Toledo-Aral JJ, Méndez-Ferrer S, Pardal R, Echevarría M, Lápez-Barneo J. Trophic restoration of the nigrostriatal dopaminergic pathway in long-term carotid body-grafted parkinsonian rats. J. Neurosci. 23, 141-148 (2003).
30. Arjona V, Mínguez-Castellanos A, Montoro RJ et al. Autotransplantation of human carotid body cell aggregates for treatment of Parkinson's disease. Neurosurgery 53, 321-328 (2003).
31. Mínguez-Castellanos A, Escamilla-Sevilla F, Hotton GR et al. Carotid body autotransplantation in Parkinson disease. A clinical and positron emission tomography study. J. Neurol. Neurosurg. Psychiatry 78, 825-831 (2007).
32. Shukla S, Agrawal AK, Chaturvedi RK et al. Co-transplantation of carotid body and ventral mesencephalic cells as an alternative approach towards functional restoration in 6-hydroxydopamine-lesioned rats. implications for Parkinson's disease. J. Neurochem. 91, 274-284 (2004).
33. Lápez-Barneo J, Pardal R, Ortega-Sáenz P, Durán R, Villadiego J, Toledo-Aral JJ. The neurogenic niche in the carotid body and its applicability to antiparkinsonian cell therapy. J. Neural Transm. 116, 975-982 (2009).
34. Villadiego J, Méndez-Ferrer S, Valdés- Sánchez T et al. Selective glial cell linederived neurotrophic factor production in adult dopaminergic carotid body cells in situ and after intrastriatal transplantation. J. Neurosci. 25, 4091-4098 (2005).
35. Hudson JL, Van Horne CG, Stromberg I et al. Correlation of apomorphine and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res. 626, 167-174 (1993).
36. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. Academic Press, NY, USA (1986).
37. Schallert T, Kozlowski DA, Humm JL, Cocke RR. Use-dependent structural events in recovery of function. Adv. Neurol. 73, 229-238 (1997).
38. West MJ, Slomianka L, Gundersen HJG. Unbiased stereological estimation of the total number of neurons of the rat hippocampus using the optical fractionator. Anat. Rec. 231, 482-497 (1991).
39. Gundersen HJG, Jensen EB. The efficiency of systematic sampling in stereology and its prediction. J. Microsc. 147, 229-263 (1987).
40. Gundersen HJG, Bendsen TF, Korbo L, Marcussen N, Moller A, Nielsen K. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APIMS 96, 379-394 (1988).
41. Abrous DN, Shaltot AR, Torres EM, Dunnett SB. Dopamine-rich grafts in the neostriatum and/or nucleus accumbens. Effects on drug-induced behaviours and skilled paw-reaching. Neuroscience 53, 187-197 (1993).
42. Brundin P, Isacson O, Björklund A. Monitoring of cell viability in suspensions of embryonic CNS tissue and its use as a criterion for intracerebral graft survival. Brain Res. 331, 251-259 (1985).
43. Hao G, Yao Y, Wang J, Zhang L, Viroonchatapan N, Wang ZZ. Intrastriatal grafting of glomus cells ameliorates behavioral defects of Parkinsonian rats. Physiol. Behav. 77, 519-525 (2002).
44. Björklund A, Rosenblad C, Winkler C, Kirik D. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol. Dis. 4, 186-200 (1997).
45. Lápez-Martín E, Caruncho HJ, Rodríguez- Pallares J, Guerra MJ, Labandeira-García JL. Striatal dopaminergic afferents concentrate in GDNF-positive patches during development and in developing intrastriatal striatal grafts. J. Comp. Neurol. 406, 199-206 (1999).
46. Pascual A, Hidalgo-Figueroa M, Piruat JI, Pintado CO, Gámez-Díaz R, Lápez-Barneo J. Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat. Neurosci. 11, 755-761 (2008).
47. Bowenkamp KE, Hoffman AF, Gerhardt GA et al. Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. J. Comp. Neurol. 355, 479-388 (1995).
48. Winkler C, Sauer H, Lee CS, Björklund A. Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease. J. Neurosci. 16, 7206-7215 (1996).
49. Kordower JH, Emborg ME, Bloch J et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290, 767-773 (2000).
50. Georgievska B, Kirik D, Björklund A. Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. Exp. Neurol. 177, 461-474 (2002).
51. Georgievska B, Kirik D, Björklund A. Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time- and dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system. J. Neurosci. 24, 6437-6445 (2004).
52. Eslamboli A, Georgievska B, Ridley RM et al. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. J. Neurosci. 25, 769-777 (2005).
53. Kordower JH, Palfi S, Chen EY et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann. Neurol. 46, 419-424 (1999).
54. Nutt JG, Burchiel KJ, Comella CL et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60, 69-73 (2003).
55. Patel NK, Bunnage M, Plaha P, Svendsen CN, Heywood P, Gill SS. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD. A two-year outcome study. Ann. Neurol. 57, 298-302 (2005).
56. Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J. Neurosurg. 102, 216-222 (2005).
57. Leitner ML, Wang LH, Osborne PA, Golden JP, Milbrandt J, Johnson EM Jr. Expression and function of GDNF family ligands and receptors in the carotid body. Exp. Neurol. 191(Suppl. 1), S68-S79 (2005).
58. Porzionato A, Macchi V, Parenti A, De Caro R. Trophic factors in the carotid body. Int. Rev. Cell Mol. Biol. 269, 1-58 (2008).
59. Erickson JT, Brosenitsch TA, Katz DM. Brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor are required simultaneously for survival of dopaminergic primary sensory neurons in vivo. J. Neurosci. 21, 581-589 (2001).
60. Hyman C, Hofer M, Barde YA et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350, 230-232 (1991).
61. Poulsen KT, Armanini MP, Klein RD, Hynes MA, Phillips HS, Rosenthal A. TGF beta 2 and TGF beta 3 are potent survival factors for midbrain dopaminergic neurons. Neuron 13, 1245-1252 (1994).
62. Luquin MR, Manrique M, Guillén J, Arbizu J, Ordoñez C, Marcilla I. Enhanced GDNF expression in dopaminergic cells of monkeys grafted with carotid body cell aggregates. Brain Res. 1375, 120-127 (2011).
63. Lopez-Barneo J, Pardal R, Ortega-Sáenz P. Cellular mechanism of oxygen sensing. Annu. Rev. Physiol. 63, 259-287 (2001).
64. Pardal R, Ortega-Sáenz P, Durán R, Lápez-Barneo J. Glia-like stem cells sustain physiologic neurogenesis in the adult mammalian carotid body. Cell 131, 364-377 (2007).
65. Brundin P, Karlsson J, Emgård M et al. Improving the survival of grafted dopaminergic neurons: a review over current approaches. Cell Transplant. 9, 179-195 (2000).
66. Karlsson J, Emgård M, Brundin P. Comparison between survival of lazaroidtreated embryonic nigral neurons in cell suspensions, cultures and transplants. Brain Res. 955, 268-280 (2002).
67. Nakao N, Frodl EM, Widner H et al. Overexpressing Cu/Zn superoxide dismutase enhances survival of transplanted neurons in a rat model of Parkinson's disease. Nat. Med. 1, 226-231 (1995).
68. Kaminski Schierle GS, Hansson O, Brundin P. Flunarizine improves the survival of grafted dopaminergic neurons. Neuroscience 94, 17-20 (1999).
69. Schierle GS, Hansson O, Leist M, Nicotera P, Widner H, Brundin P. Caspase inhibition reduces apoptosis and increases survival of nigral transplants. Nat. Med. 5, 97-100 (1999).
70. Marchionini DM, Collier TJ, Pitzer MR, Sortwell CE. Reassessment of caspase inhibition to augment grafted dopamine neuron survival. Cell Transplant. 13, 273-282 (2004).
71. Terpstra BT, Collier TJ, Marchionini DM, Levine ND, Paumier KL, Sortwell CE. Increased cell suspension concentration augments the survival rate of grafted tyrosine hydroxylase immunoreactive neurons. J. Neurosci. Methods 166, 13-19 (2007).
72. Nikkhah G, Olsson M, Eberhard J, Bentlage C, Cunningham MG, Björklund A. A microtransplantation approach for cell suspension grafting in the rat Parkinson model: a detailed account of the methodology. Neuroscience 63, 57-72 (1994).
73. Alemdar AY, Sadi D, McAlister VC, Mendez I. Liposomal formulations of tacrolimus and rapamycin increase graft survival and fiber outgrowth of dopaminergic grafts. Cell Transplant. 13, 263-271 (2004).
74. Alemdar AY, Sadi D, McAlister V, Mendez I. Intracerebral co-transplantation of liposomal tacrolimus improves xenograft survival and reduces graft rejection in the hemiparkinsonian rat. Neuroscience 146, 213-224 (2007).
75. Karlsson J, Petersén A, Gidö G, Wieloch T, Brundin P. Combining neuroprotective treatment of embryonic nigral donor tissue with mild hypothermia of the graft recipient. Cell Transplant. 14, 301-309 (2005).
76. Willing AE, Othberg AI, Saporta S et al. Sertoli cells enhance the survival of co-transplanted dopamine neurons. Brain Res. 822, 246-250 (1999).
77. Alemdar AY, Baker KA, Sadi D, McAlister VC, Mendez I. Liposomal tacrolimus administered systemically and within the donor cell suspension improves xenograft survival in hemiparkinsonian rats. Exp. Neurol. 172, 416-424 (2001).